Loading…
DIA Europe 2019 has ended
View analytic
Wednesday, February 6 • 10:45 - 11:45
#S0601: From Faster Regulatory Approval to Actual Patient Access: What Could be Done to Increase Certainty around Clinical Benefit and Predictability of Decision Making?

Sign up or log in to save this to your schedule and see who's attending!

Component Type: Session

Compelling value demonstration is critical in securing patient access to new treatment options today and in the future and even more so for products potentially undergoing accelerated pathways. On the basis of case studies, panellists will present new approaches that could be explored and will highlight what they see as opportunities and important learning.

Chair

Claudine Sapède, PharmD

Speaker

Bridging Clinical Trials to the Real World at Times of Launch – A Case Study in Alzheimer’s Disease
Michael Happich, PhD

A Case Study in Addressing Comparative Effectiveness Evidence Gaps in Personalised Medicine
Jessica Davies, MPH



Speakers
avatar for Jessica Davies

Jessica Davies

Senior Data Scientist, RWD Collaborations, F. Hoffmann-La Roche Ltd
avatar for Michael Happich

Michael Happich

HTA director, Eli Lilly
Michael Happich is International Health Technology Assessment (HTA) director at Eli Lilly based in Bad Homburg, Germany. He leads a team of HTA & RWE scientists to support international drug launches, HTA submissions and observational research in the autoimmune, pain and neurology... Read More →
avatar for Claudine Sapède

Claudine Sapède

Global HTA and Payment Policy Lead, F. Hoffmann-La Roche
Claudine Sapède is Global HTA and Payment Policy Lead at Roche based in Basel. She works on the development of Roche’s external policy positions and projects on market access related subjects including HTA and pricing. She has been working in the field of reimbursement, market... Read More →


Wednesday February 6, 2019 10:45 - 11:45
K1 Austria Center Vienna Bruno-Kreisky-Platz 1 1220 Vienna Austria
  • Featured Topics Value and Access
  • Tags Session